Chattem offering
This article was originally published in The Rose Sheet
Executive Summary
Consumer products marketer is postponing public offering of 1.8 mil. shares due to unfavorable market conditions, Chattem says June 28. Chattem initially announced plans for the offering June 17 and had expected to complete it by early July. Offering was estimated to net $60 mil., which would be used to retire bank debt and fund future acquisitions (1"The Rose Sheet" June 24, 2002, p. 12)...
You may also be interested in...
Chattem Acquisition Fund Expected To Reach $40 Mil. With Offering
Chattem is hoping to net approximately $60 mil. from a new share offering that will be used to retire bank debt and fund future acquisitions. Announced June 17, the offering of 1.8 mil. shares is expected to be complete in early July, Chattem said
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.